C-Reactive Protein for Early Diagnosis and Severity Monitoring in Melioidosis: A Systematic Review and Meta-Analysis
Issued Date
2025-09-01
Resource Type
eISSN
20751729
Scopus ID
2-s2.0-105017322643
Journal Title
Life
Volume
15
Issue
9
Rights Holder(s)
SCOPUS
Bibliographic Citation
Life Vol.15 No.9 (2025)
Suggested Citation
Phongphithakchai A., Chatatikun M., Tangpong J., Laklaeng S.N., Huang J.C., Wongyikul P., Phinyo P., Thanasai J., Khemla S., Chanthot C., Chittamma A., Klangbud W.K. C-Reactive Protein for Early Diagnosis and Severity Monitoring in Melioidosis: A Systematic Review and Meta-Analysis. Life Vol.15 No.9 (2025). doi:10.3390/life15091360 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112428
Title
C-Reactive Protein for Early Diagnosis and Severity Monitoring in Melioidosis: A Systematic Review and Meta-Analysis
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Melioidosis, caused by Burkholderia pseudomallei, is a serious infectious disease in Southeast Asia and northern Australia. Methods: We systematically reviewed observational studies measuring C-reactive protein (CRP) in laboratory-confirmed melioidosis for diagnosis, severity assessment, or outcome evaluation. PubMed, Embase, and Scopus were searched up to May 2025. Data were pooled using a random-effects model; heterogeneity was quantified (I<sup>2</sup>). Results: Seven studies (n = 451) were included. The pooled mean CRP level in melioidosis was 74.37 mg/L (95% Confidence Interval [CI], 32.76–168.83; I<sup>2</sup> = 99.1%), considerably higher than healthy reference values (<10 mg/L). Conclusions: CRP is consistently raised in melioidosis and may aid in early diagnosis and severity monitoring, although high heterogeneity limits the precision of pooled estimates. Integration of CRP into multimodal prediction tools, rather than use in isolation, is recommended. Further prospective studies should define optimal diagnostic thresholds.